Document is current
Any future updates will be listed below
-
Authors
Devi-Marulkar, Priyanka
Fastenackels, Solène
Karapentiantz, Pierre
Goc, Jérémy http://orcid.org/0000-0002-4214-8877
Germain, Claire
Kaplon, Hélène
Knockaert, Samantha
Olive, Daniel
Panouillot, Marylou
Validire, Pierre
Damotte, Diane
Alifano, Marco
Murris, Juliette http://orcid.org/0000-0002-7017-9865
Katsahian, Sandrine
Lawand, Myriam
Dieu-Nosjean, Marie-Caroline http://orcid.org/0000-0002-1697-8914
-
Funding
Funding for this research was provided by:
Fondation ARC pour la Recherche sur le Cancer
Ligue Contre le Cancer
“Institut National de la Santé et de la Recherche Médicale (INSERM), the “Institut National du Cancer” (INCa-DGOS_10888, Dieu-Nosjean), Sorbonne Université, and Université de Paris.
- License Information
-
More Information
Article History
Received: 7 March 2021
Accepted: 9 December 2022
First Online: 24 December 2022
Competing interests
: M.-C.D.-N. is listed as a co-inventor of four patents (including one with J.G., C.G., and P.D.-M. as co-inventors, too) regarding the method for the prognosis of survival time of a patient suffering from a solid cancer that is owned by Inserm and Inserm Transfert. D.O. is cofounder and shareholder of Imcheck Therapeutics, Emergence Therapeutics and Alderaan Biotechnology. The remaining authors declare no competing interests.
: Written informed consent before their inclusion in the study was obtained from all patients. Protocols were approved by the local ethics and human investigation committees (nos. 2008-133, 2012-0612 and 2017-A03081-52), in the application of article L.1121-1 of the French Public Health Code.
